Clinical Trial Update: A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening) [Phase 3]

View source ↗

Summary

Phase 3 master protocol trial of Orforglipron (LY3502970) in adults with hypertension and overweight/obesity, currently recruiting under the ATTAIN-Hypertension…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertension
• Obesity

Drugs mentioned

• Orforglipron (orforglipron)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Hypertension | Phase 3 | Status: RECRUITING